Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Total Current Liabilities (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Total Current Liabilities for 13 consecutive years, with $310.3 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 83.3% to $310.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $310.3 million through Dec 2025, up 83.3% year-over-year, with the annual reading at $310.3 million for FY2025, 83.3% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $310.3 million at Madrigal Pharmaceuticals, down from $391.4 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $391.4 million in Q3 2025, with the low at $48.8 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $134.8 million, with a median of $107.0 million recorded in 2023.
  • The sharpest move saw Total Current Liabilities rose 0.75% in 2023, then skyrocketed 120.08% in 2025.
  • Over 5 years, Total Current Liabilities stood at $76.8 million in 2021, then surged by 50.83% to $115.9 million in 2022, then grew by 2.29% to $118.5 million in 2023, then soared by 42.79% to $169.3 million in 2024, then surged by 83.3% to $310.3 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $310.3 million, $391.4 million, and $196.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.